Highlights of this edition include our community response to ICH's Public Consultation on GCP E6(R3) Guideline and our commentary in Lancet Psychiatry - "Fast tracking informative clinical trials: lessons for mental health".
Following Lord O’Shaughnessy’s new review into commercial clinical trials, Professor Sir Martin Landray has co-authored an article for The Lancet exploring how the UK can deliver on the recommendations outlined in the review.
To commemorate Clinical Trials Day this year, we are kicking off a new content series, #GoodTrialsGrapevine, where we invite clinical trials experts and thought leaders to share their perspectives on key themes in clinical research; what makes a good trial and why.
Recent policy initiatives have called for clinical trials to be strengthened as a response to future pandemics. We argue that similar efforts must be made to improve the trials landscape for non-communicable diseases, particularly mental health.
The year ahead will see major initiatives take significant steps in shaping the future of clinical trials globally. From the anticipated public consultation on updated ICH Good Clinical Practice guidance to new World Health Organization (WHO) Guidance on Best Practices for Clinical Trials...
The Collaborative responded to a recent call for input from the White House Office for Science & Technology Policy on how the U.S. and the world can mount a better clinical trials response to future health emergencies. Our response makes five recommendations on priority actions.